Biology-based combined-modality radiotherapy: workshop report.
OBJECTIVE
The purpose of this workshop summary is to provide an overview of preclinical and clinical data on combined-modality radiotherapy.


METHODS
The 8th Annual Radiation Workshop at Round Top was held April 13-16, 2000 at the International Festival Institute (Round Top, TX).


RESULTS
Presentations by 30 speakers (from Germany, Netherlands, Australia, England, and France along with U.S. participants and M. D. Anderson Cancer Center faculty) formed the framework for discussions on the current status and future perspectives of biology-based combined-modality radiotherapy.


CONCLUSIONS
Cellular and molecular pathways available for radiation modification by chemical and biologic agents are numerous, providing new opportunities for translational research in radiation oncology and for more effective combined-modality treatment of cancer.
Mason
K A
KA
Department of Experimental Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. kmason@mdanderson.org
Komaki
R
R
Cox
J D
JD
Milas
L
L
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D011905:Genes, ras / Q000187:drug effects; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011853:Radiobiology
D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D004791:Enzyme Inhibitors; D006133:Growth Substances; D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents